APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Human Endostatin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Human Endostatin Market Outlook and Growth Opportunities 2026

Report ID 174031490426 December 2025194 pages

Choose your research edition.

Industry ResearchRecombinant Human Endostatin Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Human Endostatin Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Recombinant Human Endostatin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Human Endostatin Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Human Endostatin Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Recombinant Human Endostatin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Human Endostatin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Human Endostatin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Human Endostatin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Human Endostatin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Human Endostatin market include Thermo Fisher Scientific and PeproTech among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Human Endostatin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Human Endostatin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Human Endostatin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Human Endostatin market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Human Endostatin Segment by Company

Thermo Fisher Scientific

PeproTech

Recombinant Human Endostatin Segment by Type

Purity:95%

Others

Recombinant Human Endostatin Segment by Application

Medical Care

Scientific Research

Others

Recombinant Human Endostatin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant Human Endostatin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Recombinant Human Endostatin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Human Endostatin significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Human Endostatin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Endostatin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Endostatin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Endostatin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Human Endostatin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Human Endostatin industry.

Chapter 3: Detailed analysis of Recombinant Human Endostatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Recombinant Human Endostatin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Recombinant Human Endostatin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Human Endostatin Industry Trends Table 2. Recombinant Human Endostatin Industry Drivers Table 3. Recombinant Human Endostatin Industry Opportunities and Challenges Table 4. Recombinant Human Endostatin Industry Restraints Table 5. Global Recombinant Human Endostatin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Human Endostatin Revenue Share by Company (2021-2026) Table 7. Global Recombinant Human Endostatin Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Recombinant Human Endostatin Sales Volume Share by Company (2021-2026) Table 9. Global Recombinant Human Endostatin Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Recombinant Human Endostatin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Recombinant Human Endostatin Key Company Manufacturing Base & Headquarters Table 12. Global Recombinant Human Endostatin Company, Product Type & Application Table 13. Global Recombinant Human Endostatin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Human Endostatin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Purity:95% Table 18. Significant Companies of Others Table 19. Global Recombinant Human Endostatin Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Recombinant Human Endostatin Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Recombinant Human Endostatin Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Recombinant Human Endostatin Sales Volume Share by Type (2021-2026) Table 23. Global Recombinant Human Endostatin Sales Volume Share by Type (2027-2032) Table 24. Global Recombinant Human Endostatin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Recombinant Human Endostatin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Recombinant Human Endostatin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Recombinant Human Endostatin Sales Value Share by Type (2021-2026) Table 28. Global Recombinant Human Endostatin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Medical Care Table 30. Significant Companies of Scientific Research Table 31. Significant Companies of Others Table 32. Global Recombinant Human Endostatin Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Recombinant Human Endostatin Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Recombinant Human Endostatin Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Recombinant Human Endostatin Sales Volume Share by Application (2021-2026) Table 36. Global Recombinant Human Endostatin Sales Volume Share by Application (2027-2032) Table 37. Global Recombinant Human Endostatin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Recombinant Human Endostatin Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Recombinant Human Endostatin Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Recombinant Human Endostatin Sales Value Share by Application (2021-2026) Table 41. Global Recombinant Human Endostatin Sales Value Share by Application (2027-2032) Table 42. Global Recombinant Human Endostatin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Recombinant Human Endostatin Sales by Region (2021-2026) & (K Units) Table 44. Global Recombinant Human Endostatin Sales Market Share by Region (2021-2026) Table 45. Global Recombinant Human Endostatin Sales by Region (2027-2032) & (K Units) Table 46. Global Recombinant Human Endostatin Sales Market Share by Region (2027-2032) Table 47. Global Recombinant Human Endostatin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Recombinant Human Endostatin Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Recombinant Human Endostatin Sales Value Share by Region (2021-2026) Table 50. Global Recombinant Human Endostatin Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Recombinant Human Endostatin Sales Value Share by Region (2027-2032) Table 52. Global Recombinant Human Endostatin Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Recombinant Human Endostatin Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Recombinant Human Endostatin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Recombinant Human Endostatin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Recombinant Human Endostatin Sales by Country (2021-2026) & (K Units) Table 57. Global Recombinant Human Endostatin Sales Market Share by Country (2021-2026) Table 58. Global Recombinant Human Endostatin Sales by Country (2027-2032) & (K Units) Table 59. Global Recombinant Human Endostatin Sales Market Share by Country (2027-2032) Table 60. Global Recombinant Human Endostatin Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Recombinant Human Endostatin Sales Value Market Share by Country (2021-2026) Table 62. Global Recombinant Human Endostatin Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Recombinant Human Endostatin Sales Value Market Share by Country (2027-2032) Table 64. Thermo Fisher Scientific Company Information Table 65. Thermo Fisher Scientific Business Overview Table 66. Thermo Fisher Scientific Recombinant Human Endostatin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Thermo Fisher Scientific Recombinant Human Endostatin Product Portfolio Table 68. Thermo Fisher Scientific Recent Development Table 69. PeproTech Company Information Table 70. PeproTech Business Overview Table 71. PeproTech Recombinant Human Endostatin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. PeproTech Recombinant Human Endostatin Product Portfolio Table 73. PeproTech Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. Recombinant Human Endostatin Distributors List Table 77. Recombinant Human Endostatin Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Recombinant Human Endostatin Product Image Figure 2. Global Recombinant Human Endostatin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Human Endostatin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Recombinant Human Endostatin Sales (2021-2032) & (K Units) Figure 5. Global Recombinant Human Endostatin Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Recombinant Human Endostatin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Purity:95% Image Figure 10. Others Image Figure 11. Global Recombinant Human Endostatin Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Recombinant Human Endostatin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Recombinant Human Endostatin Sales Volume Share by Type (2021-2032) Figure 14. Global Recombinant Human Endostatin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Recombinant Human Endostatin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Recombinant Human Endostatin Sales Value Share by Type (2021-2032) Figure 17. Medical Care Image Figure 18. Scientific Research Image Figure 19. Others Image Figure 20. Global Recombinant Human Endostatin Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Recombinant Human Endostatin Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Recombinant Human Endostatin Sales Volume Share by Application (2021-2032) Figure 23. Global Recombinant Human Endostatin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Recombinant Human Endostatin Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Recombinant Human Endostatin Sales Value Share by Application (2021-2032) Figure 26. Global Recombinant Human Endostatin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Recombinant Human Endostatin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Recombinant Human Endostatin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Recombinant Human Endostatin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Recombinant Human Endostatin Sales Value (2021-2032) & (US$ Million) Figure 31. North America Recombinant Human Endostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Recombinant Human Endostatin Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Recombinant Human Endostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Recombinant Human Endostatin Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Recombinant Human Endostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Recombinant Human Endostatin Sales Value (2021-2032) & (US$ Million) Figure 37. South America Recombinant Human Endostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Recombinant Human Endostatin Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Recombinant Human Endostatin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Recombinant Human Endostatin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Recombinant Human Endostatin Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Recombinant Human Endostatin Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Purity:95%
  • Others
Applications
  • Medical Care
  • Scientific Research
  • Others
Companies covered
  • Thermo Fisher Scientific
  • PeproTech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Human Endostatin Sales Value (2021-2032)
  4. 1.2.2 Global Recombinant Human Endostatin Sales Volume (2021-2032)
  5. 1.2.3 Global Recombinant Human Endostatin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Recombinant Human Endostatin Market Dynamics
  1. 2.1 Recombinant Human Endostatin Industry Trends
  2. 2.2 Recombinant Human Endostatin Industry Drivers
  3. 2.3 Recombinant Human Endostatin Industry Opportunities and Challenges
  4. 2.4 Recombinant Human Endostatin Industry Restraints
3 Recombinant Human Endostatin Market by Company
  1. 3.1 Global Recombinant Human Endostatin Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Human Endostatin Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Human Endostatin Sales Volume by Company (2021-2026)
  4. 3.4 Global Recombinant Human Endostatin Average Price by Company (2021-2026)
  5. 3.5 Global Recombinant Human Endostatin Company Ranking (2024-2026)
  6. 3.6 Global Recombinant Human Endostatin Company Manufacturing Base and Headquarters
  7. 3.7 Global Recombinant Human Endostatin Company Product Type and Application
  8. 3.8 Global Recombinant Human Endostatin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Recombinant Human Endostatin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Recombinant Human Endostatin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Recombinant Human Endostatin Market by Type
  1. 4.1 Recombinant Human Endostatin Type Introduction
  2. 4.1.1 Purity:95%
  3. 4.1.2 Others
  4. 4.2 Global Recombinant Human Endostatin Sales Volume by Type
  5. 4.2.1 Global Recombinant Human Endostatin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant Human Endostatin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Recombinant Human Endostatin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Recombinant Human Endostatin Sales Value by Type
  9. 4.3.1 Global Recombinant Human Endostatin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant Human Endostatin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Recombinant Human Endostatin Sales Value Share by Type (2021-2032)
5 Recombinant Human Endostatin Market by Application
  1. 5.1 Recombinant Human Endostatin Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Scientific Research
  4. 5.1.3 Others
  5. 5.2 Global Recombinant Human Endostatin Sales Volume by Application
  6. 5.2.1 Global Recombinant Human Endostatin Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Recombinant Human Endostatin Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Recombinant Human Endostatin Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Recombinant Human Endostatin Sales Value by Application
  10. 5.3.1 Global Recombinant Human Endostatin Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Recombinant Human Endostatin Sales Value by Application (2021-2032)
  12. 5.3.3 Global Recombinant Human Endostatin Sales Value Share by Application (2021-2032)
6 Recombinant Human Endostatin Regional Sales and Value Analysis
  1. 6.1 Global Recombinant Human Endostatin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Human Endostatin Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Human Endostatin Sales by Region: 2021-2026
  4. 6.2.2 Global Recombinant Human Endostatin Sales by Region (2027-2032)
  5. 6.3 Global Recombinant Human Endostatin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Recombinant Human Endostatin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Recombinant Human Endostatin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Recombinant Human Endostatin Sales Value by Region (2027-2032)
  9. 6.5 Global Recombinant Human Endostatin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Recombinant Human Endostatin Sales Value (2021-2032)
  12. 6.6.2 North America Recombinant Human Endostatin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Recombinant Human Endostatin Sales Value (2021-2032)
  15. 6.7.2 Europe Recombinant Human Endostatin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Recombinant Human Endostatin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Recombinant Human Endostatin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Recombinant Human Endostatin Sales Value (2021-2032)
  21. 6.9.2 South America Recombinant Human Endostatin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Recombinant Human Endostatin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Recombinant Human Endostatin Sales Value Share by Country, 2025 VS 2032
7 Recombinant Human Endostatin Country-level Sales and Value Analysis
  1. 7.1 Global Recombinant Human Endostatin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Human Endostatin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Recombinant Human Endostatin Sales by Country (2021-2032)
  4. 7.3.1 Global Recombinant Human Endostatin Sales by Country (2021-2026)
  5. 7.3.2 Global Recombinant Human Endostatin Sales by Country (2027-2032)
  6. 7.4 Global Recombinant Human Endostatin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Recombinant Human Endostatin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Recombinant Human Endostatin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Recombinant Human Endostatin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Recombinant Human Endostatin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Recombinant Human Endostatin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific Recombinant Human Endostatin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Recombinant Human Endostatin Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 PeproTech
  8. 8.2.1 PeproTech Company Information
  9. 8.2.2 PeproTech Business Overview
  10. 8.2.3 PeproTech Recombinant Human Endostatin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 PeproTech Recombinant Human Endostatin Product Portfolio
  12. 8.2.5 PeproTech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Human Endostatin Value Chain Analysis
  2. 9.1.1 Recombinant Human Endostatin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Human Endostatin Sales Mode & Process
  6. 9.2 Recombinant Human Endostatin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Human Endostatin Distributors
  9. 9.2.3 Recombinant Human Endostatin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst